

Response to questions – Senator McCarthy

- **Program 4.3:** Pharmaceutical Benefits Advisory Committee recommendations – Please provide an updated list of outstanding Pharmaceutical Benefits Advisory Committee (PBAC) recommendations since 2013 (noting the new “Medicine Status Website” does not include any recommendations made before July 2019).

Please see **Attachment X**

Medicines recommended by the PBAC which are being progressed by the Department of Health

The Medicine Status website (MSW) now contains all PBAC recommendations from July 2019 onwards. The Department of Health is negotiating with sponsors who have received a positive recommendation to reach an agreement that is consistent with the PBAC recommendation. This website is updated regularly so that the public can monitor the listing steps. The MSW can be accessed at www.pbs.gov.au/medicinesstatus/home.html

The table below outlines medicines recommended by the PBAC prior to July 2019 PBAC meeting, and therefore not listed on the MSW, and where the sponsor company has indicated that they wish to proceed to a listing but that listing is not finalised.

Table 1: current as at 20 October 2020

PBAC Meeting March 2019		
ALIROCUMAB Praluent®	Hypercholesterolaemia	No listing proposal received from sponsor that is consistent with PBAC recommendation
BUDESONIDE Entocort®	Mild to moderate Crohn disease	No listing proposal received from sponsor that is consistent with PBAC recommendation
CERTOLIZUMAB PEGOL Cimzia®	Severe chronic plaque psoriasis	No listing proposal received from sponsor that is consistent with PBAC recommendation
PBAC Meeting March 2018		
RAMUCIRUMAB (Cyramza®)	Advanced gastric or gastro-oesophageal junction adenocarcinomas	No listing proposal received from sponsor that is consistent with PBAC recommendation
RANOLAZINE (Ranexa®)	Stable angina pectoris	No listing proposal received from sponsor that is consistent with PBAC recommendation
PBAC Meeting November 2017		
SEVELAMER Renvela®	Hyperphosphataemia in patients with chronic kidney disease	No listing proposal received from sponsor
PBAC Meeting March 2017		
TENOFOVIR ALAFENAMIDE Vemlidy®	Chronic hepatitis B	No listing proposal received from sponsor that is consistent with PBAC recommendation

Medicines recommended by the PBAC prior to July 2019, where the sponsor company has advised that it will not be progressing the recommendation and therefore it is not possible for the Government to list on the PBS

Table 2: Current as of 20 October 2020

MEDICINE	INDICATION
PBAC meeting March 2019	
BUDESONIDE Budenofalk®	Crohn disease
PBAC Meeting November 2018	
SARILUMAB Injection 200mg in 1.14mL	Rheumatoid arthritis
PBAC Meeting July 2018	
ADALIMUMAB Amgevita®	Multiple indications
ADALIMUMAB Hadlima®	Severe active rheumatoid arthritis
ARIPIRAZOLE Abilify Maintena®	Schizophrenia
MENINGOCOCCAL POLYSACCHARIDE SERO (GROUPS A, C, W-135 AND Y) OLIGOSACCHARIDE CONJUGATE VACCINE	Meningococcal disease
PBAC meeting March 2018	
CETUXIMAB Erbitux®	squamous cell carcinoma of the head and neck
TENECTEPLASE Metalyse®	Acute myocardial infarction
PBAC meeting November 2017	
CANAKINUMAB Ilaris®	Cryopyrin associated periodic syndromes (CAPS)
RADIUM (223Ra) Xofigo®	Metastatic castrate resistant prostate cancer (mCRPC)
PBAC meeting July 2017	
ADALIMUMAB Humira®	Multiple indications
PBAC meeting March 2017	
RITUXIMAB MabThera SC®	Chronic lymphocytic leukaemia
PBAC meeting November 2016	
PARITAPREVIR WITH RITONAVIR WITH OMBITASVIR Technivie®	Hepatitis C
PBAC meeting July 2016	
ADRENALINE Adrenaline Auto Inject Sun-JV®	Anaphylaxis
ALENDRONIC ACID Binosto®	Osteoporosis
DENOSUMAB Xgeva®	Hypercalcaemia of malignancy
PBAC meeting March 2016	
TRIGLYCERIDES MEDIUM CHAIN Peptamen Junior Liquid® Peptamen Junior Advance®	Multiple indications
PBAC meeting November 2015	
THYROXINE Eltroxin®	Thyroid hormone deficiency